OABI
OmniAb Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$196.90M
P/E Ratio
—
EPS
$-0.57
Beta
0.87
52W High
$2.29
52W Low
$1.22
50-Day MA
$1.66
200-Day MA
$1.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About OmniAb Inc.
OmniAb Inc. is a pioneering biotechnology firm focused on the creation of fully human therapeutic antibodies through its cutting-edge OmniAb platform. This unique technology facilitates the rapid discovery and refinement of high-efficacy therapeutics to tackle a diverse range of diseases. By fostering strategic partnerships and collaborations, OmniAb strives to expedite drug development and broaden access to innovative therapies. With an experienced leadership team and a strong product pipeline, the company is well-positioned to seize expanding opportunities within the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $18.67M |
| Gross Profit (TTM) | $18.36M |
| EBITDA | $-46.89M |
| Operating Margin | -147.40% |
| Return on Equity | -23.40% |
| Return on Assets | -13.00% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $1.85 |
| Price-to-Book | 0.76 |
| Price-to-Sales (TTM) | 10.55 |
| EV/Revenue | 9.05 |
| EV/EBITDA | -10.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -22.50% |
| Shares Outstanding | $144.78M |
| Float | $97.34M |
| % Insiders | 15.22% |
| % Institutions | 52.10% |
Historical Volatility
HV 10-Day
64.59%
HV 20-Day
51.18%
HV 30-Day
49.47%
HV 60-Day
52.11%
HV Rank
16.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.33 target)
7
BuyData last updated: 4/30/2026